检索结果-南通市图书馆

Forge ahead and improve the core competitiveness of Animal Models and Experimental Medicine(AMEM)

在线全文

学校读者我要写书评

暂无评论

Animal Models and Experimental Medicine 2023年第1期6卷 2-2页

作者： jian-dong jiang Academician of Chinese Academy of Engineering Editor-in-Chief of Acta Pharmaceutica Sinica BChairmanDepartment of PharmacologyPeking Union Medical College&Chinese Academy of Medical SciencesBeijingChina

After 5 years of accumulation, Animal Models and Experimental Medicine(AMEM) has received 396 manuscripts from 46 countries and regions, including Chinese mainland, Iran, the United States, India, Israel, Nigeria, Brazil, Bangladesh, Sri Lanka, the Netherlands, Denmark, Australia, Japan, and Spain. It has become an important international exchange and display platform for innovative research results in the field of laboratory animal science and basic medicine.

关键词： competitiveness mainland Israel

Our endeavor to write a new chapter in the development of laboratory animal sciences

在线全文

学校读者我要写书评

暂无评论

Animal Models and Experimental Medicine 2022年第1期5卷 2-2页

作者： jian-dong jiang Acta Pharmaceutica Sinica B Chinese Academy of Engineering Department of Pharmacology Peking Union Medical College&Chinese Academy of Medical SciencesBeijingChina

Since the beginning of the 21st century,with the wide application of molecular biology and genetic engineering technology,the more holistic discipline of laboratory animal sciences has also developed rapidly and many excellent innovations based on laboratory animals,animal models and experimental medicine have continued to emerge.Animal Models and Experimental Medicine(AMEM)was launched in 2018,which was timely and attracted the attention of the industry.Four years have passed and AMEM has achieved fruitful results.

关键词： continued fruitful passed

Morinda officinalis oligosaccharides increase serotonin in the brain and ameliorate depression via promoting 5-hydroxytryptophan production in the gut microbiota

在线全文

学校读者我要写书评

暂无评论

Acta Pharmaceutica Sinica B 2022年第8期12卷 3298-3312页

作者： Zheng-Wei Zhang Chun-Sheng Gao Heng Zhang jian Yang Ya-Ping Wang Li-Bin Pan Hang Yu Chi-Yu He Hai-Bin Luo Zhen-Xiong Zhao Xin-Bo Zhou Yu-Li Wang Jie Fu Pei Han Yu-Hui dong Gang Wang Song Li Yan Wang jian-dong jiang Wu Zhong State Key Laboratory of Bioactive Substance and Function of Natural Medicines Institute of Materia MedicaChinese Academy of Medical Sciences/Peking Union Medical CollegeBeijing 100050China Beijing Institute of Pharmacology and Toxicology Beijing 100000China Beijing Synchrotron Radiation Facility Institute of High Energy PhysicsChinese Academy of SciencesBeijing 100049China The National Clinical Research Center for Mental Disorders&Beijing Key Laboratory of Mental Disorders Beijing Anding HospitalCapital Medical UniversityBeijing 100088China Advanced Innovation Center for Human Brain Protection Capital Medical UniversityBeijing 100069China School of Pharmaceutical Sciences Hainan UniversityHainan 570228China National Engineering Research Center for the Emergence Drugs Beijing 100000China

Morinda officinalis oligosaccharides(MOO) are an oral drug approved in China for the treatment of depression in China. However, MOO is hardly absorbed so that their anti-depressant mechanism has not been elucidated. Here, we show that oral MOO acted on tryptophan → 5-hydroxytryptophan(5-HTP) → serotonin(5-HT) metabolic pathway in the gut microbiota. MOO could increase tryptophan hydroxylase levels in the gut microbiota which accelerated 5-HTP production from tryptophan;meanwhile, MOO inhibited 5-hydroxytryptophan decarboxylase activity, thus reduced 5-HT generation,and accumulated 5-HTP. The raised 5-HTP from the gut microbiota was absorbed to the blood, and then passed across the blood-brain barrier to improve 5-HT levels in the brain. Additionally, pentasaccharide,as one of the main components in MOO, exerted the significant anti-depressant effect through a mechanism identical to that of MOO. This study reveals for the first time that MOO can alleviate depression via increasing 5-HTP in the gut microbiota.

关键词： Depression Morinda oficinalis oligosaccharides Gut microbiota Tryptophan hydroxylase 5-Hydroxytryptophan decarboxylase 5-Hydroxytryptophan Serotonin Drug metabolism

Establishment of drug-resistant HBV small-animal models by hydrodynamic injection

在线全文

学校读者我要写书评

暂无评论

Acta Pharmaceutica Sinica B 2014年第4期4卷 270-276页

作者： Junjun Cheng Yanxing Han jian-dong jiang State Key Laboratory of Bioactive Substances and Function of Natural Medicine Institute of Materia MedicaChinese Academy of Medical SciencesBeijing 100050China

In antiviral therapy of hepatitis B virus(HBV)infection,drug resistance remains a huge obstacle to the long-term effectiveness of nucleoside/tide analogs(NAs).Primary resistance mutation(rtM204V)contributes to lamivudine(LAM)-resistance,and compensatory mutations(rtL180M and rtV173L)restore viral fitness and increase replication efficiency.The evaluation of new anti-viral agents against drug-resistant HBV is limited by the lack of available small-animal models.We established LAM-resistance HBV replication mice models based on clinical LAM-resistant HBV mutants.Double(rtM204VþrtL180M)or triple(rtM204VþrtL180MþrtV173L)lamivudine-resistant mutations were introduced into HBV expression vector,followed by hydrodynamic injection into tail vein of NOD/SCID mice.Viremia was detected on days 5,9,13 and 17 and liver HBV DNA was detected on day 17 after injection.The serum and liver HBV DNA levels in LAM-resistant model carrying triple mutations are the highest among the models.Two NAs,LAM and entecavir(ETV),were used to test the availability of the models.LAM and ETV inhibited viral replication on wild-type model.LAM was no longer effective on LAM-resistant models,but ETV retains a strong activity.Therefore,these models can be used to evaluate anti-viral agents against lamivudine-resistance,affording new opportunities to establish other drug-resistant HBV small-animal models.

关键词： Drug-resistance Animal models Hepatitis B virus Hydrodynamic injection

Recent advances in the anti-HCV mechanisms of interferon

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Acta Pharmaceutica Sinica B 2014年第4期4卷 241-247页

作者： Menghao Huang jian-dong jiang Zonggen Peng Institute of Medicinal Biotechnology Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100050China Institute of Materia Medica Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100050China

Interferon(IFN)in combination with ribavirin has been the standard of care(SOC)for chronic hepatitis C for the past few decades.Although the current SOC lacks the desired efficacy,and 4 new direct-acting antiviral agents have been recently approved,interferons are still likely to remain the cornerstone of therapy for some time.Moreover,as an important cytokine system of innate immunity,host interferon signaling provides a powerful antiviral response.Nevertheless,the mechanisms by which HCV infection controls interferon production,and how interferons,in turn,trigger anti-HCV activities as well as control the outcome of HCV infection remain to be clarified.In this report,we review current progress in understanding the mechanisms of IFN against HCV,and also summarize the knowledge of induction of interferon signaling by HCV infection.

关键词： Interferon Hepatitis C virus Antiviral agent Molecular mechanism

Multi-Omics-Guided Discovery of Omicsynins Produced by Streptomyces sp.1647:Pseudo-Tetrapeptides Active Against Influenza A Viruses and Coronavirus HCoV-229E

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Engineering 2022年第9期16卷 176-186页

作者： Hongmin Sun Xingxing Li Minghua Chen Ming Zhong Yihua Li Kun Wang Yu Du Xin Zhen Rongmei Gao Yexiang Wu Yuanyuan Shi Liyan Yu Yongsheng Che Yuhuan Li jian-dong jiang Bin Hong Shuyi Si NHC Key Laboratory of Biotechnology of Antibiotics Institute of Medicinal BiotechnologyChinese Academy of Medical Sciences&Peking Union Medical CollegeBeijing 100050China CAMS Key Laboratory of Synthetic Biology for Drug Innovation Institute of Medicinal BiotechnologyChinese Academy of Medical Sciences&Peking Union Medical CollegeBeijing 100050China CAMS Key Laboratory of Antiviral Drug Research Institute of Medicinal BiotechnologyChinese Academy of Medical Sciences&Peking Union Medical CollegeBeijing 100050China

Many microorganisms have mechanisms that protect cells against attack from viruses.The fermentation components of Streptomyces sp.1647 exhibit potent anti-influenza A virus(IAV)activity.This strain was isolated from soil in southern China in the 1970s,but the chemical nature of its antiviral substance(s)has remained unknown until now.We used an integrated multi-omics strategy to identify the antiviral agents from this streptomycete.The antibiotics and Secondary Metabolite Analysis Shell(antiSMASH)analysis of its genome sequence revealed 38 biosynthetic gene clusters(BGCs)for secondary metabolites,and the target BGCs possibly responsible for the production of antiviral components were narrowed down to three BGCs by bioactivity-guided comparative transcriptomics analysis.Through bioinformatics analysis and genetic manipulation of the regulators and a biosynthetic gene,cluster 36 was identified as the BGC responsible for the biosynthesis of the antiviral compounds.Bioactivity-based molecular networking analysis of mass spectrometric data from different recombinant strains illustrated that the antiviral compounds were a class of structural analogues.Finally,18 pseudo-tetrapeptides with an internal ureido linkage,omicsynins A1–A6,B1–B6,and C1–C6,were identified and/or isolated from fermentation broth.Among them,11 compounds(omicsynins A1,A2,A6,B1–B3,B5,B6,C1,C2,and C6)are new compounds.Omicsynins B1–B4 exhibited potent antiviral activity against IAV with the 50%inhibitory concentration(IC_(50))of approximately 1μmol·L^(-1)and a selectivity index(SI)ranging from 100 to 300.Omicsynins B1–B4 also showed significant antiviral activity against human coronavirus HCoV-229E.By integrating multi-omics data,we discovered a number of novel antiviral pseudo-tetrapeptides produced by Streptomyces sp.1647,indicating that the secondary metabolites of microorganisms are a valuable source of novel antivirals.

关键词： Multi-omics Anti-influenza A virus Anti-coronavirus Streptomyces sp.1647 Pseudo-tetrapeptides

Hepatitis C: From inflammatory pathogenesis to antiinflammatory/hepatoprotective therapy

在线全文

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2018年第47期24卷 5297-5311页

作者： Hu Li Meng-Hao Huang jian-dong jiang Zong-Gen Peng Institute of Medicinal Biotechnology Chinese Academy of Medical Sciences and Peking Union Medical College Division of Gastroenterology and Hepatology Department of Medicine Indiana University School of Medicine Institute of Materia Medica Chinese Academy of Medical Sciences and Peking Union Medical College

Hepatitis C virus(HCV) infection commonly causes progressive liver diseases that deteriorate from chronic inflammation to fibrosis, cirrhosis and even to hepatocellular carcinoma. A long-term, persistent and uncontrolled inflammatory response is a hallmark of these diseases and further leads to hepatic injury and more severe disease progression. The levels of inflammatory cytokines and chemokines change with the states of infection and treatment, and therefore, they may serve as candidate biomarkers for disease progression and therapeutic effects. The mechanisms of HCV-induced inflammation involve classic pathogen pattern recognition, inflammasome activation, intrahepatic inflammatory cascade response, and oxidative and endoplasmic reticulum stress. Direct-acting antivirals(DAAs) are the first-choice therapy for effectively eliminating HCV, but DAAs alone are not sufficient to block the uncontrolled inflammation and severe liver injury in HCV-infected individuals. Some patients who achieve a sustained virologic response after DAA therapy are still at a long-term risk for progression to liver cirrhosis and hepatocellular carcinoma. Therefore, coupling with antiinflammatory/hepatoprotective agents with anti-HCV effects is a promising therapeutic regimen for these patients during or after treatment with DAAs. In this review, we discuss the relationship between inflammatory mediators and HCV infection, summarize the mechanismsof HCV-induced inflammation, and describe the potential roles of anti-inflammatory/hepatoprotective drugs with anti-HCV activity in the treatment of advanced HCV infection.

关键词： Hepatitis C virus infection Liver disease Inflammatory pathogenesis Anti-inflammatory and hepatoprotective therapy

Berberine is a new mechanism drug against energy metabolic disorder

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

中国药理学与毒理学杂志 2017年第10期31卷 946-947页

作者： jian-dong jiang The Institutes of Pharmaceutical Sciences Chinese Academy of Medical Sciences Beijing 100050 China

Berberine (BBR) is a natural compound isolated from Coptis chinensis and for decades an over-the-count medicine in China for bacterial-caused diarrhea. We have identified BBR to be an effective drug in treating hyperlipidemia as well as hyperglycemia. Clinical studies showed that oral administration of BBR caused significant reduction of blood cholesterol, LDL-c, triglyceride, as well as glucose and HbA1c in patients with hyperlipidemia or T2D. A small % of patients have minor and transient side- effect in the GI system. The cholesterol- lowering effect was associated with the ERK mediated LDLR mRNA up-regulation; the glucose-lowering effect mainly resulted from PKD-mediated insulin receptor expression as well as activation of AMPK. The clinical efficacy of BBR were verified by a large number of independent clinical groups in and outside China. For BBR absorption mechanism, we showed that BBR was first converted into dhBBR by nitroreductase in the gut microbiota, promoting BBR enter into intestinal well, where it was oxidized back to BBR, and then got into blood. Our recent study showed that BBR could also promote gut microbiota pathways to make SCFAs (such as butyrate), which entered blood and reduced blood lipids and glucose, suggesting a newly identified MOA of BBR. BBR is now in clinical trial in China. We consider it a multiple-target drug for metabolic disorders in clinic.

关键词： berberine dhBBR hyperlipidemia hyperglycemia

Berberine treats atherosclerosis via a vitamine-like effect downregulating Choline-TMA-TMAO production pathway in gut microbiota

在线全文

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2022年第8期7卷 3008-3020页

作者： Shu-Rong Ma Qian Tong Yuan Lin Li-Bin Pan Jie Fu Ran Peng Xian-Feng Zhang Zhen-Xiong Zhao Yang Li Jin-Bo Yu Lin Cong Pei Han Zheng-Wei Zhang Hang Yu Yan Wang jian-dong jiang State Key Laboratory of Bioactive Substance and Function of Natural Medicines Institute of Materia MedicaChinese Academy of Medical Sciences/Peking Union Medical CollegeBeijingChina The First Hospital of Jilin University ChangchunChina

Trimethylamine-N-oxide(TMAO)derived from the gut microbiota is an atherogenic metabolite.This study investigates whether or not berberine(BBR)could reduce TMAO production in the gut microbiota and treat atherosclerosis.Effects of BBR on TMAO production in the gut microbiota,as well as on plaque development in atherosclerosis were investigated in the culture of animal intestinal bacterial,HFD-fed animals and atherosclerotic patients,respectively.We found that oral BBR in animals lowers TMAO biosynthesis in intestine through interacting with the enzyme/co-enzyme of choline-trimethylamine lyase(CutC)and flavincontaining monooxygenase(FMO)in the gut microbiota.This action was performed by BBR’s metabolite dihydroberberine(a reductive BBR by nitroreductase in the gut microbiota),via a vitamine-like effect down-regulating Choline-TMA-TMAO production pathway.Oral BBR decreased TMAO production in animal intestine,lowered blood TMAO and interrupted plaque formation in blood vessels in the HFD-fed hamsters.Moreover,21 patients with atherosclerosis exhibited the average decrease of plaque score by 3.2%after oral BBR(0.5 g,bid)for 4 months(^(*)P<0.05,n=21);whereas the plaque score in patients treated with rosuvastatin plus aspirin,or clopidogrel sulfate or ticagrelor(4 months,n=12)increased by 1.9%.TMA and TMAO in patients decreased by 38 and 29%in faeces(^(*)P<0.05;^(*)P<0.05),and 37 and 35%in plasma(^(***)P<0.001;^(*)P<0.05),after 4 months on BBR.BBR might treat atherosclerotic plaque at least partially through decreasing TMAO in a mode of action similar to that of vitamins.

关键词： vitamin intestine TMAO